文献速递抗栓抗凝管理

倾向评分加权与匹配在达比加群与华法林比较研究中的差异

Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
PubMed 文献 · Drug Saf · 2017-01-01

该研究基于2010年10月至2012年12月抗凝药初始用药者队列,比较倾向评分匹配与两种加权方法(IPTW和SMR加权)在达比加群与华法林比较中的结果差异。匹配法显示卒中HR 0.77(95%CI 0.54-1.09),大出血HR 0.75(95%CI 0.65-0.87);IPTW结果显著不同,而SMR加权与匹配结果相近,提示IPTW需截断极端权重并报告权重信息。

要点

  • 匹配法显示达比加群较华法林卒中HR 0.77(95%CI 0.54-1.09),大出血HR 0.75(95%CI 0.65-0.87)。
  • IPTW法得出卒中HR 0.00(95%CI 0.00-0.56),大出血HR 0.08(95%CI 0.08-0.10),与匹配法差异显著。
  • SMR加权法与匹配法结果相近,卒中HR 0.65(95%CI 0.42-1.03),大出血HR 0.73(95%CI 0.61-0.85)。

核心结论

  • 同一倾向评分不同应用方式可导致研究结果显著不同,IPTW法尤为明显,截断极端权重可改善此问题。

研究设计与样本

  • 队列研究,纳入2010年10月至2012年12月抗凝药初始用药者,达比加群23,543例,华法林50,288例,匹配形成19,189对。

主要发现

  • 匹配法卒中HR 0.77(95%CI 0.54-1.09),大出血HR 0.75(95%CI 0.65-0.87)。
  • IPTW法卒中HR 0.00(95%CI 0.00-0.56),大出血HR 0.08(95%CI 0.08-0.10),与匹配法差异显著。
  • SMR加权法卒中HR 0.65(95%CI 0.42-1.03),大出血HR 0.73(95%CI 0.61-0.85),与匹配法差异较小。

临床怎么用

  • 使用IPTW时应报告所应用的权重信息并进行敏感性分析,以避免研究结果被错误呈现并增强解释性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Comparing medications in observational settings requires differences in patient characteristics to be accounted for. Propensity score (PS) methods can address these differences, but PS weighting approaches may introduce bias. METHODS: Within a cohort study of anticoagulant initiators from October 2010 through to December 2012, PS values for dabigatran relative to warfarin were estimated, and study outcomes (stroke or major bleeding) among the cohort were identified. The PS was used to match initiators and results compared with those obtained using inverse probability of treatment weighting (IPTW) and standardized morbidity ratio (SMR) weighting. Hazard ratios (HRs) for study outcomes were estimated using a proportional hazards regression model. RESULTS: There were 23,543 dabigatran and 50,288 warfarin initiators, and matching formed 19,189 pairs (81.5% of dabigatran initiators) which resulted in a pooled stroke HR of 0.77 (95% confidence interval [CI] 0.54-1.09), and a pooled major hemorrhage HR of 0.75 (95% CI 0.65-0.87). The IPTW results for stroke (HR = 0.00; 95% CI 0.00-0.56) and major hemorrhage (HR = 0.08; 95% CI 0.08-0.10) substantially differed, while the SMR-weighted results for stroke (HR = 0.65; 95% CI 0.42-1.03) and major hemorrhage (HR = 0.73; 95% CI 0.61-0.85) differed only slightly from matching. CONCLUSIONS: In this example, different applications of the same PS led to substantially different results, a finding that was particularly apparent with IPTW, and this was remedied by truncating extreme weights. If IPTW is used, information regarding the weights applied along with sensitivity analyses could avoid misrepresentation of study results, and would enhance their interpretation.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Seeger JD, Bykov K, Bartels DB, et al. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Drug Saf. 2017. PMID: 27900668. doi:10.1007/s40264-016-0480-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。